Both oroxylin A treatment and XPC knockdown augment anti-cancer efficacy of cisplatin in vitro, indicating that oroxylin A alleviates hypoxia-induced cisplatin resistance at least partly through downregulating XPC. Here, XPC is linked to cancer.